Participated in Fathom Therapeutics' $47M Series A, led by Sutter Hill Ventures.
APR 2026
Develops small-molecule therapeutics using its Microcosmos drug discovery platform, which combines quantum chemistry, physics-based modeling, AI, and lab-in-the-loop experimentation to predict and control protein behavior in living cells
Develops small-molecule therapeutics using its Microcosmos drug discovery platform, which combines quantum chemistry, physics-based modeling, AI, and lab-in-the-loop experimentation to predict and control protein behavior in living cells. The platform aims to design highly selective medicines with fewer off-target effects. The company has internal discovery programs and active discovery partnerships, with a lead program reported in animal efficacy studies.